Horizon Pharma Inc (HZNP) 38.45 $HZNP
Horizon Pharma
at Investor's Business Daily - Tue Jul 21, 5:45PM CDT
Horizon Pharma (HZNP) increased its unsolicited bid for Depomed (DEPO), offering a deal worth $33 a share in Horizon stock. It had previously bid $29.25 a share. Horizon shares rose 0.4% to 38.45. Depomed rose 1.7% to 33.28.
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma Up on Expected Q2 Sales, 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 5:35PM CDT
Horizon Pharma (HZNP) was up 3.3% after the company announced encouraging expected net sales for the second quarter of 2015 and upped its 2015 guidance.
HZNP: 38.45 (+0.14), LGND: 104.35 (-1.22), ANAC: 149.31 (+1.18), AMAG: 72.59 (-1.83)
Horizon Raises Bid for Specialty Pharma Company Depomed
at The Street - Tue Jul 21, 5:32PM CDT
The offer comes just three months after Depomed purchases the diabetes-related pain drug Nucynta from a subsidiary of Johnson & Johnson.
JNJ: 100.34 (-0.03), HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma raises bid for Depomed to $33 per share
AP - Tue Jul 21, 11:33AM CDT
NEW YORK (AP) — Drugmaker Horizon Pharma PLC is boosting its offer for fellow drugmaker Depomed to $33 per share.
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Depomed Confirms Receipt of Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc
PR Newswire - Tue Jul 21, 10:23AM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company"
today confirmed that it has received a purported revised, highly conditional, unsolicited; and non-binding proposal from Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" to acquire all of the outstanding shares of Depomed in an all-stock transaction currently valued at $33.00 per share (the "Revised Proposal".
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma Raises Bid For Depomed; Both Stocks Up
at Investor's Business Daily - Tue Jul 21, 9:50AM CDT
Specialty drugmaker Horizon Pharma (HZNP) raised its unsolicited offer for Depomed (DEPO) Wednesday, sending both stocks up. Horizon proposed a deal worth $33 a share, all in Horizon stock, up from its earlier bid of $29.25, which Depomed rejected....
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma plc Increases Offer for Depomed, Inc. to $33.00 per Share
Marketwired - Tue Jul 21, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that it has increased the value of its all-stock acquisition proposal to $33.00 per share from $29.25 per share, contingent on Depomed entering into good faith discussions regarding a transaction. The increased offer represents a 60 percent premium to the closing price of Depomed on July 6, 2015, the day prior to when Horizon's initial proposal was made public.
HZNP: 38.45 (+0.14)
'Mad Money' Lightning Round: You Want Yahoo!
at The Street - Tue Jul 21, 5:00AM CDT
Cramer says to stay away from Alibaba but go for Yahoo!
YHOO: 39.73 (+0.19), UA: 88.34 (-0.61), NLY: 9.77 (-0.04), WWE: 17.23 (+0.34), HZNP: 38.45 (+0.14), CSCO: 27.84 (-0.19), VGR: 24.69 (-0.14), BABA: 82.54 (-0.13)
Jim Cramer's 'Mad Money' Recap: Earnings Tsunami Heads Our Way
at The Street - Mon Jul 20, 7:31PM CDT
Cramer says you've got to listen to the commentary on earnings from Apple tomorrow, not to mention what's up with Microsoft and falling PC sales.
WWE: 17.23 (+0.34), DAL: 44.65 (+0.56), PYPL: 39.35 (-1.12), SBUX: 56.20 (-0.01), YHOO: 39.73 (+0.19), JNJ: 100.34 (-0.03), QCOM: 65.14 (+1.35), CMG: 673.07 (-4.93), HZNP: 38.45 (+0.14), RCPT: 228.98 (+0.26), AAL: 40.90 (+0.35), ABBV: 70.54 (-0.26), GOOGL: 695.35 (+2.51), CAT: 82.22 (-0.03), MSFT: 47.28 (+0.36), AAPL: 130.75 (-1.32), CSCO: 27.84 (-0.19), AMBA: 118.18 (+0.46), JOY: 29.01 (-0.59), KO: 41.19 (-0.19), AMZN: 488.00 (-0.10), ABT: 49.76 (-0.30), AXP: 78.95 (-0.35), FB: 98.39 (+0.48), LLY: 85.57 (-2.30), BA: 145.00 (-1.72), CELG: 136.24 (+1.01), NFLX: 112.51 (+1.96), UA: 88.34 (-0.61), NLY: 9.77 (-0.04), MCD: 97.32 (-0.17), VGR: 24.69 (-0.14), BABA: 82.54 (-0.13)
Stocks Turn Slightly Higher; Horizon Jumps On Outlook
at Investor's Business Daily - Mon Jul 20, 12:31PM CDT
Stocks turned small losses into modest gains Monday afternoon. Thanks to solar, online travel and software stocks, the Nasdaq led with a 0.3% gain. The Dow Jones industrial average and the S&P 500 rose 0.2% each. Earlier, the Nasdaq and the S&P 500...
FB: 98.39 (+0.48), MDSO: 56.64 (-3.24), HZNP: 38.45 (+0.14), HRTG: 25.20 (+0.26), TASR: 32.63 (+0.08)
Horizon Pharma Hits High As Q2 Sales Beat Street
at Investor's Business Daily - Mon Jul 20, 10:57AM CDT
Specialty drugmaker Horizon Pharma (HZNP) jumped to a new high in early trading Monday after it issued strong preliminary Q2 sales and raised its full-year guidance. Horizon said sales in the quarter were about $170 million to $172 million, roughly a...
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma (HZNP) Stock Gains on Strong Guidance
at The Street - Mon Jul 20, 9:46AM CDT
Horizon Pharma (HZNP) shares are rising after the company provided upside second quarter and full year revenue guidance.
HZNP: 38.45 (+0.14)
Horizon Pharma plc Expects Record Net Sales Results for Second Quarter 2015 and Raises Full-Year 2015 Net Sales and Adjusted EBITDA Guidance
Marketwired - Mon Jul 20, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced expected record net sales results for the second quarter ended June 30, 2015.
HZNP: 38.45 (+0.14)
Critical Alerts For Chesapeake Energy, Starbucks, Horizon Pharma, Halozyme Therapeutics and Citigroup Released By InvestorsObserver
PR Newswire - Fri Jul 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CHK, SBUX, HZNP, HALO and C.
SBUX: 56.20 (-0.01), HALO: 23.77 (-0.77), CHK: 9.29 (-0.98), C: 59.10 (+0.25), HZNP: 38.45 (+0.14)
Depomed
at Investor's Business Daily - Mon Jul 13, 5:54PM CDT
Depomed (DEPO) stated in a regulatory filing that it has adopted a "poison pill" plan following Horizon Pharma's (HZNP) $2.1 bil hostile takeover bid, which Depomed has rejected. Depomed shares rose 1.2% to 30.51. Horizon Pharma fell 2.7% to 34.97.
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma plc Responds to Depomed's Adoption of a Poison Pill
Marketwired - Mon Jul 13, 11:50AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today responded to the announcement by Depomed, Inc. that it has implemented a poison pill (also known as a "shareholder rights plan" and amended and restated its bylaws in a shareholder unfriendly manner.
HZNP: 38.45 (+0.14)
Will Horizon Pharma (HZNP) Stock be Hurt by DepoMed's Poison Pill?
at The Street - Mon Jul 13, 9:35AM CDT
Horizon Pharma (HZNP) shares are showing volatility after the object of its takeover interest, DepoMed (DEPO), adopted a poison pill to dissuade any further unsolicited offers.
HZNP: 38.45 (+0.14)
Horizon Pharma elects Tina E. Ventura as VP of Investor Relations
M2 - Fri Jul 10, 3:36AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) reported on Thursday the appointment of Tina E. Ventura as vice president of its investor relations.
HZNP: 38.45 (+0.14)
New Studies & Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials
PR Newswire - Thu Jul 09, 7:30AM CDT
Researchers & Biotech companies are constantly searching for tailor-made treatment plans for bone marrow conditions such as aplastic anemia as part of an emerging precision medicine movement which likely will help doctors optimize treatment for this rare and deadly blood condition. Even with the Biotechnology struggling a bit this week in markets, companies in focus today with news and current developments are Regen BioPharma, Inc. (OTCBB: RGBP), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), Horizon Pharma plc (NASDAQ: HZNP), AstraZeneca Pharmaceuticals Co. (NYSE: AZN) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
RPTP: 15.00 (-0.34), IRWD: 11.29 (+0.11), AZN: 67.64 (-0.21), HZNP: 38.45 (+0.14), OCLS: 1.44 (-0.02)
Horizon Pharma
at Investor's Business Daily - Tue Jul 21, 5:45PM CDT
Horizon Pharma (HZNP) increased its unsolicited bid for Depomed (DEPO), offering a deal worth $33 a share in Horizon stock. It had previously bid $29.25 a share. Horizon shares rose 0.4% to 38.45. Depomed rose 1.7% to 33.28.
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma Up on Expected Q2 Sales, 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 5:35PM CDT
Horizon Pharma (HZNP) was up 3.3% after the company announced encouraging expected net sales for the second quarter of 2015 and upped its 2015 guidance.
HZNP: 38.45 (+0.14), LGND: 104.35 (-1.22), ANAC: 149.31 (+1.18), AMAG: 72.59 (-1.83)
Horizon Raises Bid for Specialty Pharma Company Depomed
at The Street - Tue Jul 21, 5:32PM CDT
The offer comes just three months after Depomed purchases the diabetes-related pain drug Nucynta from a subsidiary of Johnson & Johnson.
JNJ: 100.34 (-0.03), HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma raises bid for Depomed to $33 per share
AP - Tue Jul 21, 11:33AM CDT
NEW YORK (AP) — Drugmaker Horizon Pharma PLC is boosting its offer for fellow drugmaker Depomed to $33 per share.
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Depomed Confirms Receipt of Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc
PR Newswire - Tue Jul 21, 10:23AM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company"
today confirmed that it has received a purported revised, highly conditional, unsolicited; and non-binding proposal from Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" to acquire all of the outstanding shares of Depomed in an all-stock transaction currently valued at $33.00 per share (the "Revised Proposal". HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma Raises Bid For Depomed; Both Stocks Up
at Investor's Business Daily - Tue Jul 21, 9:50AM CDT
Specialty drugmaker Horizon Pharma (HZNP) raised its unsolicited offer for Depomed (DEPO) Wednesday, sending both stocks up. Horizon proposed a deal worth $33 a share, all in Horizon stock, up from its earlier bid of $29.25, which Depomed rejected....
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma plc Increases Offer for Depomed, Inc. to $33.00 per Share
Marketwired - Tue Jul 21, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that it has increased the value of its all-stock acquisition proposal to $33.00 per share from $29.25 per share, contingent on Depomed entering into good faith discussions regarding a transaction. The increased offer represents a 60 percent premium to the closing price of Depomed on July 6, 2015, the day prior to when Horizon's initial proposal was made public.
HZNP: 38.45 (+0.14)
'Mad Money' Lightning Round: You Want Yahoo!
at The Street - Tue Jul 21, 5:00AM CDT
Cramer says to stay away from Alibaba but go for Yahoo!
YHOO: 39.73 (+0.19), UA: 88.34 (-0.61), NLY: 9.77 (-0.04), WWE: 17.23 (+0.34), HZNP: 38.45 (+0.14), CSCO: 27.84 (-0.19), VGR: 24.69 (-0.14), BABA: 82.54 (-0.13)
Jim Cramer's 'Mad Money' Recap: Earnings Tsunami Heads Our Way
at The Street - Mon Jul 20, 7:31PM CDT
Cramer says you've got to listen to the commentary on earnings from Apple tomorrow, not to mention what's up with Microsoft and falling PC sales.
WWE: 17.23 (+0.34), DAL: 44.65 (+0.56), PYPL: 39.35 (-1.12), SBUX: 56.20 (-0.01), YHOO: 39.73 (+0.19), JNJ: 100.34 (-0.03), QCOM: 65.14 (+1.35), CMG: 673.07 (-4.93), HZNP: 38.45 (+0.14), RCPT: 228.98 (+0.26), AAL: 40.90 (+0.35), ABBV: 70.54 (-0.26), GOOGL: 695.35 (+2.51), CAT: 82.22 (-0.03), MSFT: 47.28 (+0.36), AAPL: 130.75 (-1.32), CSCO: 27.84 (-0.19), AMBA: 118.18 (+0.46), JOY: 29.01 (-0.59), KO: 41.19 (-0.19), AMZN: 488.00 (-0.10), ABT: 49.76 (-0.30), AXP: 78.95 (-0.35), FB: 98.39 (+0.48), LLY: 85.57 (-2.30), BA: 145.00 (-1.72), CELG: 136.24 (+1.01), NFLX: 112.51 (+1.96), UA: 88.34 (-0.61), NLY: 9.77 (-0.04), MCD: 97.32 (-0.17), VGR: 24.69 (-0.14), BABA: 82.54 (-0.13)
Stocks Turn Slightly Higher; Horizon Jumps On Outlook
at Investor's Business Daily - Mon Jul 20, 12:31PM CDT
Stocks turned small losses into modest gains Monday afternoon. Thanks to solar, online travel and software stocks, the Nasdaq led with a 0.3% gain. The Dow Jones industrial average and the S&P 500 rose 0.2% each. Earlier, the Nasdaq and the S&P 500...
FB: 98.39 (+0.48), MDSO: 56.64 (-3.24), HZNP: 38.45 (+0.14), HRTG: 25.20 (+0.26), TASR: 32.63 (+0.08)
Horizon Pharma Hits High As Q2 Sales Beat Street
at Investor's Business Daily - Mon Jul 20, 10:57AM CDT
Specialty drugmaker Horizon Pharma (HZNP) jumped to a new high in early trading Monday after it issued strong preliminary Q2 sales and raised its full-year guidance. Horizon said sales in the quarter were about $170 million to $172 million, roughly a...
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma (HZNP) Stock Gains on Strong Guidance
at The Street - Mon Jul 20, 9:46AM CDT
Horizon Pharma (HZNP) shares are rising after the company provided upside second quarter and full year revenue guidance.
HZNP: 38.45 (+0.14)
Horizon Pharma plc Expects Record Net Sales Results for Second Quarter 2015 and Raises Full-Year 2015 Net Sales and Adjusted EBITDA Guidance
Marketwired - Mon Jul 20, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced expected record net sales results for the second quarter ended June 30, 2015.
HZNP: 38.45 (+0.14)
Critical Alerts For Chesapeake Energy, Starbucks, Horizon Pharma, Halozyme Therapeutics and Citigroup Released By InvestorsObserver
PR Newswire - Fri Jul 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CHK, SBUX, HZNP, HALO and C.
SBUX: 56.20 (-0.01), HALO: 23.77 (-0.77), CHK: 9.29 (-0.98), C: 59.10 (+0.25), HZNP: 38.45 (+0.14)
Depomed
at Investor's Business Daily - Mon Jul 13, 5:54PM CDT
Depomed (DEPO) stated in a regulatory filing that it has adopted a "poison pill" plan following Horizon Pharma's (HZNP) $2.1 bil hostile takeover bid, which Depomed has rejected. Depomed shares rose 1.2% to 30.51. Horizon Pharma fell 2.7% to 34.97.
HZNP: 38.45 (+0.14), DEPO: 33.28 (+0.55)
Horizon Pharma plc Responds to Depomed's Adoption of a Poison Pill
Marketwired - Mon Jul 13, 11:50AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today responded to the announcement by Depomed, Inc. that it has implemented a poison pill (also known as a "shareholder rights plan"
and amended and restated its bylaws in a shareholder unfriendly manner. HZNP: 38.45 (+0.14)
Will Horizon Pharma (HZNP) Stock be Hurt by DepoMed's Poison Pill?
at The Street - Mon Jul 13, 9:35AM CDT
Horizon Pharma (HZNP) shares are showing volatility after the object of its takeover interest, DepoMed (DEPO), adopted a poison pill to dissuade any further unsolicited offers.
HZNP: 38.45 (+0.14)
Horizon Pharma elects Tina E. Ventura as VP of Investor Relations
M2 - Fri Jul 10, 3:36AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) reported on Thursday the appointment of Tina E. Ventura as vice president of its investor relations.
HZNP: 38.45 (+0.14)
New Studies & Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials
PR Newswire - Thu Jul 09, 7:30AM CDT
Researchers & Biotech companies are constantly searching for tailor-made treatment plans for bone marrow conditions such as aplastic anemia as part of an emerging precision medicine movement which likely will help doctors optimize treatment for this rare and deadly blood condition. Even with the Biotechnology struggling a bit this week in markets, companies in focus today with news and current developments are Regen BioPharma, Inc. (OTCBB: RGBP), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), Horizon Pharma plc (NASDAQ: HZNP), AstraZeneca Pharmaceuticals Co. (NYSE: AZN) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
RPTP: 15.00 (-0.34), IRWD: 11.29 (+0.11), AZN: 67.64 (-0.21), HZNP: 38.45 (+0.14), OCLS: 1.44 (-0.02)
